drugset / Trial / NCT01005641
ELBA: Exemestane and Lapatinib in Advanced Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Aromatase inhibitors are the standard treatment for hormone responsive advanced breast cancer. The combination of the aromatase inhibitor exemestane with with another breast cancer drug that blocks epidermal growth factor receptor (EGFR) and Erb-2 activity (lapatinib) is being studied for the possibility of improving response to therapy, and delaying resistance to endocrine therapy.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-10
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Lapatinib | Small molecule | — | Oral |